Related Experiment Videos
Long-term safety and efficacy profile of simvastatin
S J Boccuzzi1, T S Bocanegra, J F Walker
1Merck Sharp & Dohme Research Laboratories, Merck & Co. Inc., Rahway, New Jersey 07065-0914.
The American Journal of Cardiology
|November 1, 1991
Summary
Simvastatin, a cholesterol-lowering drug, was well-tolerated in over 2,400 patients. Adverse events were generally mild, with rare instances of liver enzyme elevation or myopathy, supporting its safety profile for hypercholesterolemia treatment.
Area of Science:
- Pharmacology
- Clinical Medicine
- Cardiovascular Disease
Background:
- Simvastatin is a widely used HMG-CoA reductase inhibitor for managing primary hypercholesterolemia.
- Long-term safety data is crucial for understanding the risk-benefit profile of lipid-lowering therapies.
Purpose of the Study:
- To evaluate the safety and tolerability of simvastatin in a large patient cohort.
- To assess the incidence of adverse events, including liver enzyme elevations and myopathy, during simvastatin therapy.
Main Methods:
- Analysis of safety data from approximately 2,400 patients with primary hypercholesterolemia.
- Inclusion of patients from controlled clinical studies and open extensions with a mean follow-up of 1 year.
- Assessment of drug-related clinical adverse experiences and laboratory abnormalities.
Main Results:
- Most frequent adverse events included constipation (2.5%), abdominal pain (2.2%), and flatulence (2.0%).
- Persistent elevations in transaminase levels (>3x ULN) occurred in 1% of patients, with 0.1% discontinuing therapy.
- Discontinuation due to myopathy was rare (0.08%), and no cases of hepatitis were observed.
Conclusions:
- Simvastatin demonstrates a favorable safety profile in patients with primary hypercholesterolemia.
- The drug is generally well-tolerated, with a low incidence of serious adverse events like myopathy and liver toxicity.
- Long-term simvastatin use appears safe, even in elderly patients and those with pre-existing coronary artery disease.